# Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

> **NCT02934529** · PHASE3 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 673 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Folinic Acid
- **DRUG:** 5-FU
- **DRUG:** 5-FU
- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** regorafenib
- **DRUG:** Irinotecan 125mg
- **DRUG:** Cetuximab wkly

## Key facts

- **NCT ID:** NCT02934529
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 673 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02934529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02934529, "Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02934529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*